Intellia Therapeutics (NASDAQ:NTLA) Receives Sell Rating from The Goldman Sachs Group

Intellia Therapeutics (NASDAQ:NTLA)‘s stock had its “sell” rating reaffirmed by equities researchers at The Goldman Sachs Group in a research note issued on Friday. They presently have a $9.00 target price on the stock. The Goldman Sachs Group’s target price points to a potential downside of 17.13% from the stock’s previous close.

Several other equities research analysts also recently issued reports on the stock. Chardan Capital raised their price objective on shares of Intellia Therapeutics from $88.00 to $91.00 and gave the stock a “buy” rating in a research report on Monday, November 18th. Canaccord Genuity Group reissued a “buy” rating and set a $90.00 price target on shares of Intellia Therapeutics in a research report on Tuesday, November 19th. Oppenheimer reduced their price objective on shares of Intellia Therapeutics from $60.00 to $40.00 and set an “outperform” rating on the stock in a research note on Monday, January 13th. JPMorgan Chase & Co. reiterated a “neutral” rating and set a $13.00 price target (down previously from $45.00) on shares of Intellia Therapeutics in a research report on Friday. Finally, Barclays reduced their price target on shares of Intellia Therapeutics from $76.00 to $55.00 and set an “overweight” rating on the stock in a research note on Friday, November 8th. Two research analysts have rated the stock with a sell rating, six have given a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, Intellia Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $46.06.

Intellia Therapeutics Stock Up 0.6 %

Shares of NASDAQ:NTLA opened at $10.86 on Friday. The firm has a market cap of $1.11 billion, a price-to-earnings ratio of -2.00 and a beta of 1.80. Intellia Therapeutics has a 12 month low of $8.96 and a 12 month high of $34.87. The company’s fifty day simple moving average is $10.90 and its 200 day simple moving average is $15.72.

Insider Activity

In other news, CEO John M. Leonard sold 26,807 shares of the firm’s stock in a transaction on Friday, January 3rd. The stock was sold at an average price of $12.18, for a total value of $326,509.26. Following the transaction, the chief executive officer now directly owns 941,115 shares in the company, valued at $11,462,780.70. This trade represents a 2.77 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Insiders have sold a total of 29,000 shares of company stock valued at $352,551 over the last ninety days. 3.20% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Intellia Therapeutics

Hedge funds have recently modified their holdings of the company. Regeneron Pharmaceuticals Inc. bought a new stake in Intellia Therapeutics in the 4th quarter worth approximately $43,177,000. Voloridge Investment Management LLC grew its holdings in Intellia Therapeutics by 226.8% during the 4th quarter. Voloridge Investment Management LLC now owns 1,526,994 shares of the company’s stock valued at $17,805,000 after purchasing an additional 1,059,751 shares during the last quarter. Contrarius Group Holdings Ltd bought a new stake in shares of Intellia Therapeutics during the 4th quarter worth approximately $11,798,000. Two Sigma Advisers LP boosted its stake in shares of Intellia Therapeutics by 94.5% during the fourth quarter. Two Sigma Advisers LP now owns 1,998,317 shares of the company’s stock valued at $23,300,000 after purchasing an additional 970,700 shares during the period. Finally, Two Sigma Investments LP raised its stake in shares of Intellia Therapeutics by 88.1% during the fourth quarter. Two Sigma Investments LP now owns 1,843,743 shares of the company’s stock valued at $21,498,000 after acquiring an additional 863,363 shares in the last quarter. 88.77% of the stock is currently owned by institutional investors.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.